Characterization of factor VIII inhibitors

International Journal of Hematology

Volumn 83, Issue 2, 2006, Pages 109-118

  Shima, Midori ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Alloantibody; Autoantibody; Epitope; Factor VIII; Hemophilia A; Inactivation; Inhibitor

Indexed keywords

ACTIVATED PROTEIN C; ALLOANTIBODY; AMINO ACID; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9A; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G4; MEMBRANE PHOSPHOLIPID; THROMBIN; VON WILLEBRAND FACTOR; ANTIBODY; EPITOPE; LIGAND;

AMINO TERMINAL SEQUENCE; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CRYSTALLOGRAPHY; HEMOPHILIA A; MEMBRANE BINDING; PROTEIN DOMAIN; REVIEW; BLOOD; HUMAN; IMMUNOLOGY;

ANTIBODIES; EPITOPES; FACTOR VIII; HEMOPHILIA A; HUMANS; LIGANDS;

EID: 33646839131     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.05160     Document Type: Review

References (79)

1. Kasper CK, Aledort L, Aronson D, et al. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh. 1975;34:869-872.
2. Verbruggen B, Giles A, Samis J, Verbeek K, Mensink E, Novakova I. The type of factor VIII deficient plasma used influences the performance of the Nijmegen modification of the Bethesda assay for factor VIII inhibitors. Thromb Haemost. 2001;86:1435-1439.
3. Verbruggen B, van Heerde W, Novakova I, Lillicrap D, Giles A. A 4% solution of bovine serum albumin may be used in place of factor VIII:C deficient plasma in the control sample in the Nijmegen modification of the Bethesda factor VIII:C inhibitor assay. Thromb Haemost. 2002;88:362-364.
4. White GC 2nd, Rosendaal F, Aledort LM, Lusher JM, Rothschild C, Ingerslev J, for the Factor VIII and Factor IX Subcommittee. Definitions in hemophilia: recommendation of the scientific subcommittee on factor VIII and factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost. 2001;85:560.
5. Yoshioka A, Kamisue S, Tanaka I, et al. Anamnestic response following infusion of prothrombin complex concentrates (PCC) and activated prothrombin complex concentrates (APCC) in haemophilia A patients with inhibitors. Blood Coagul Fibrinolysis. 1991;2(suppl 1):51-58.
6. Brown DL, Bray GL, Scharrer I. Transient inhibitors in patients with hemophilia A [abstract]. Thromb Haemost. 1999;82(suppl):573. Abstract 1804.
7. Hoyer LW, Gawryl MS, de la Fuente B. Immunochemical characterization of factor VIII inhibitors. Prog Clin Biol Res. 1984;150:73-85.
8. Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood. 1987;69:1475-1480.
9. Matsumoto T, Shima M, Fukuda K, et al. Immunological characterization of factor VIII autoantibodies in patients with acquired hemophilia A in the presence or absence of underlying disease. Thromb Res. 2001;104:381-388.
10. Towfighi F, Gharagozlou S, Sharifian RA, et al. Comparative measurement of anti-factor VIII antibody by Bethesda assay and ELISA reveals restricted isotype profile and epitope specificity. Acta Haematol. 2005;114:84-90.
11. Aalberse RC, van der Gaag R, van Leeuwen J. Serologic aspects of IgG4 antibodies, I: prolonged immunization results in an IgG4-restricted response. J Immunol. 1983;130:722-726.
12. Ghosh S, Rizza CR. Changes in the character of factor VIII inhibitors following factor VIII transfusion. Scand J Haematol. 1984;33:239-243.
13. Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci U S A. 1985;82:7728-7732.
14. Scandella D, DeGraaf Mahoney S, Mattingly M, Roeder D, Timmons L, Fulcher CA. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci U S A. 1988;85:6152-6156.
15. Scandella D, Mattingly M, de Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood. 1989;74:1618-1626.
16. Scandella DH. Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Semin Thromb Hemost. 2000;26:137-142.
17. Healey JF, Lubin IM, Nakai H, et al. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem. 1995;270:14505-14509.
18. Lubin IM, Healey JF, Barrow RT, Scandella D, Lollar P. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis. J Biol Chem. 1997;272:30191-30195.
19. Pemberton S, Lindley P, Zaitsev V, Card G, Tuddenham EG, Kemball-Cook GA. A molecular model for the triplicated A domains of human factor VIII based on the crystal structure of human ceruloplasmin. Blood. 1997;89:2413-2421.
20. van den Brink EN, Turenhout EA, Bank CM, Fijnvandraat K, Peters M, Voorberg J. Molecular analysis of human anti-factor VIII antibodies by V gene phage display identifies a new epitope in the acidic region following the A2 domain. Blood. 2000;96:540-545.
21. Prescott R, Nakai H, Saenko EL, et al, and the Recombinate and Kogenate Study Groups. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood. 1997;89:3663-3671.
22. Foster PA, Fulcher CA, Houghten RA, de Graaf Mahoney S, Zimmerman TS. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest. 1988;82:123-128.
23. Ware J, Toomey JR, Stafford DW. Localization of a factor VIII-inhibiting antibody epitope to a region between residues 338 and 362 of factor VIII heavy chain. Proc Natl Acad Sci U S A. 1988;85:3165-3169.
24. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII: correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry. 1986;25:505-512.
25. Stoilova-McPhie S, Villoutreix BO, Mertens K, Kemball-Cook G, Holzenburg A. 3-Dimensional structure of membrane-bound coagulation factor VIII: modeling of the factor VIII heterodimer within a 3-dimensional density map derived by electron crystallography. Blood. 2002;99:1215-1223.
26. Shibata M, Shima M, Morichika S, et al. An alloantibody recognizing the FVIII A1 domain in a patient with CRM reduced haemophilia A due to deletion of a large portion of the A1 domain DNA sequence. Thromb Haemost. 2000;84:442-448.
27. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS, for the Kogenate Previously Untreated Patient Study Group. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A: safety, efficacy, and development of inhibitors. N Engl J Med. 1993;328:453-459.
28. Sultan Y, for the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3435 hemophilia patients in France. Thromb Haemost. 1992;67:600-602.
29. Shima M, Scandella D, Yoshioka A, et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost. 1993;69:240-246.
30. Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood. 1995;86:1811-1819.
31. Shima M, Nakai H, Scandella D, et al. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Haematol. 1995;91:714-721.
32. Nogami K, Shima M, Nakai H, et al. Identification of a factor VIII peptide, residues 2315-2330, which neutralizes human factor VIII C2 inhibitor alloantibodies: requirement of Cys2326 and Glu2327 for maximum effect. Br J Haematol. 1999;107:196-203.
33. Lollar P. Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII. Thromb Haemost. 1997;78:647-651.
34. Healey JF, Barrow RT, Tamim HM, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood. 1998;92:3701-3709.
35. Kuwabara I, Maruyama H, Kamisue S, Shima M, Yoshioka A, Maruyama IN. Mapping of the minimal domain encoding a conformational epitope by lambda phage surface display: factor VIII inhibitor antibodies from haemophilia A patients. J Immunol Methods. 1999;224:89-99.
36. Pratt KP, Shen BW, Takeshima K, Davie EW, Fujikawa K, Stoddard BL. Structure of the C2 domain of human factor VIII at 1.5 Å resolution. Nature. 1999;402:439-442.
37. Barrow RT, Healey JF, Jacquemin MG, Saint-Remy JM, Lollar P. Antigenicity of putative phospholipid membrane-binding residues in factor VIII. Blood. 2001;97:169-174.
38. Jacquemin MG, Desqueper BG, Benhida A, et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood. 1998;92:496-506.
39. Spiegel PC Jr, Jacquemin M, Saint-Remy JM, Stoddard BL, Pratt KP. Structure of a factor VIII C2 domain-immunoglobulin G4κ Fab complex: identification of an inhibitory antibody epitope on the surface of factor VIII. Blood. 2001;98:13-19.
40. van den Brink EN, Turenhout EA, Davies J, et al. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes. Blood. 2000;95:558-563.
41. H1 family direct the formation of human antibodies that recognize distinct antigenic sites in the C2 domain of factor VIII. Blood. 2002;99:2828-2834.
42. Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood. 1998;92:136-142.
43. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood. 2000;95:1324-1329.
44. Qian J, Burkly LC, Smith EP, et al. Role of CD154 in the secondary immune response: the reduction of pre-existing splenic germinal centers and anti-factor VIII inhibitor titer. Eur J Immunol. 2000;30:2548-2554.
45. + T-cell epitope repertoire on the C2 domain of coagulation factor VIII. J Thromb Haemost. 2003;1:1777-1784.
46. Pratt KP, Qian J, Ellaban E, et al. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site. Thromb Haemost. 2004;92:522-528.
47. + T cells on the A3 domain of coagulation factor VIII. J Thromb Haemost. 2004;2:1385-1394.
48. Hu GL, Okita DK, Conti-Fine BM. T cell recognition of the A2 domain of coagulation factor VIII in hemophilia patients and healthy subjects. J Thromb Haemost. 2004;2:1908-1917.
49. + T cell epitope from the C1 domain of factor VIII. J Thromb Haemost. 2005;3:991-1000.
50. Hay CR, Ludlam CA, Colvin BT, et al. Factor VIII inhibitors in mild and moderate-severity haemophilia A: UK Haemophilia Centre Directors Organization. Thromb Haemost. 1998;79:762-766.
51. Fijnvandraat K, Turenhout EA, van den Brink EN, et al. The missense mutation Arg593 → Cys is related to antibody formation in a patient with mild hemophilia A. Blood. 1997;89:4371-4377.
52. Peerlinck K, Jacquemin MG, Arnout J, et al. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A. Blood. 1999;93:2267-2273.
53. Suzuki H, Shima M, Arai M, et al. Factor VIII Ise (R2159C) in a patient with mild hemophilia A, an abnormal factor VIII with retention of function but modification of C2 epitopes. Thromb Haemost. 1997;77:862-867.
54. Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood. 1982;60:1103-1109.
55. Nogami K, Shima M, Giddings JC, et al. Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis. Blood. 2001;97:669-677.
56. Walker FJ, Scandella D, Fay PJ. Identification of the binding site for activated protein C on the light chain of factors V and VIII. J Biol Chem. 1990;265:1484-1489.
57. Nogami K, Shima M, Nishiya K, et al. A novel mechanism of factor VIII protection by von Willebrand factor from activated protein C-catalyzed inactivation. Blood. 2002;99:3993-3998.
58. van Dieijen G, Tans G, Rosing J, Hemker HC. The role of phospholipid and factor VIIIa in the activation of bovine factor X. J Biol Chem. 1981;256:3433-3442.
59. Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C: cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest. 1988;82:1236-1243.
60. Saenko EL, Shima M, Gilbert GE, Scandella D. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition. J Biol Chem. 1996;271:27424-27431.
61. Foster PA, Fulcher CA, Houghten RA, Zimmerman TS. An immunogenic region within residues Val1670-Glu1684 of the factor VIII light chain induces antibodies which inhibit binding of factor VIII to von Willebrand factor. J Biol Chem. 1988;263:5230-5234.
62. Leyte A, Mertens K, Distel B, et al. Inhibition of human coagulation factor VIII by monoclonal antibodies: mapping of functional epitopes with the use of recombinant factor VIII fragments. Biochem J. 1989;263:187-194.
63. Shima M, Yoshioka A, Nakai H, et al. Epitope localization of monoclonal antibodies against factor VIII light chain which inhibit complex formation by factor VIII with von Willebrand factor. Int J Hematol. 1991;54:515-522.
64. Jacquemin M, Benhida A, Peerlinck K, et al. A human antibody directed to the factor VIII Cl. domain inhibits factor VIII cofactor activity and binding to von Willebrand factor. Blood. 2000;95:156-163.
65. Lenting PJ, van de Loo JW, Donath MJ, van Mourik JA, Mertens K. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX. J Biol Chem. 1996;271:1935-1940.
66. Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem. 1994;269:20522-20527.
67. Fijnvandraat K, Celie PH, Turenhout EA, et al. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain. Blood. 1998;91:2347-2352.
68. Fay PJ, Koshibu K. The A2 subunit of factor VIIIa modulates the active site of factor IXa. J Biol Chem. 1998;273:19049-19054.
69. Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem. 1999;274:29826-29830.
70. Parker ET, Pohl J, Blackburn MN, Lollar P. Subunit structure and function of porcine factor Xa-activated factor VIII. Biochemistry. 1997;36:9365-9373.
71. Nogami K, Shima M, Hosokawa K, et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem. 2000;275:25774-25780.
72. Nogami K, Shima M, Hosokawa K, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem. 1999;274:31000-31007.
73. Nogami K, Shima M, Nishiya K, et al. Human factor VIII inhibitor alloantibodies with a C2 epitope inhibit factor Xa-catalyzed factor VIII activation: a new anti-factor VIII inhibitory mechanism. Thromb Haemost. 2002;87:459-465.
74. Nogami K, Shima M, Nishiya K, et al. Anticoagulant effects of a synthetic peptide containing residues Thr-2253-Gln-2270 within factor VIII C2 domain that selectively inhibits factor Xa-catalysed factor VIII activation. Br J Haematol. 2002;116:868-874.
75. Nogami K, Lapan KA, Zhou Q, Wakabayashi H, Fay PJ. Identification of a factor Xa-interactive site within residues 337-372 of the factor VIII heavy chain. J Biol Chem. 2004;279:15763-15771.
76. Nogami K, Freas J, Manithody C, Wakabayashi H, Rezaie AR, Fay PJ. Mechanisms of interactions of factor X and factor Xa with the acidic region in the factor VIII A1 domain. J Biol Chem. 2004;279:33104-33113.
77. Tramontano A, Janda KD, Lerner RA. Catalytic antibodies. Science. 1986;234:1566-1570.
78. Lacroix-Desmazes S, Bayry J, Misra N, et al. The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med. 2002;346:662-667.
79. Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV. Catalytic antibodies to factor VIII in haemophilia A. Blood Coagul Fibrinolysis. 2003;14(suppl 1):S31-S34.